Want to see UTMD full AI Analyst Report?
Top Page
Utah Medical Products
(NASDAQ:UTMD)
Select Model
Select Model
Rating:75Outperform
Price Target:
$80.00
▲(12.74% Upside)
Action:Reiterated
Date:09/06/26
UTMD scores well primarily due to strong financial quality—high margins, strong cash conversion, and a near-debt-free balance sheet—partly offset by ongoing revenue and free-cash-flow contraction. Technicals are largely neutral, valuation is reasonable but not discounted, and the Orion acquisition provides a constructive (but execution-dependent) growth catalyst.
Positive Factors
Strong Profitability
UTMD’s high gross and net margins indicate meaningful profitability in its regulated medical-device portfolio. Maintaining this margin quality supports internal funding for product development, sales infrastructure, and acquisitions while providing resilience if procedure volumes fluctuate.
Negative Factors
Persistent Revenue Contraction
Repeated revenue declines point to weakening demand or market momentum across UTMD’s served product areas rather than a single quarterly fluctuation. Continued contraction could reduce operating leverage, constrain investment capacity, and make stable earnings increasingly dependent on margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
UTMD’s high gross and net margins indicate meaningful profitability in its regulated medical-device portfolio. Maintaining this margin quality supports internal funding for product development, sales infrastructure, and acquisitions while providing resilience if procedure volumes fluctuate.
Read all positive factors
Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$226.37M
Dividend Yield1.74%
Average Volume (3M)33.81K
Price to Earnings (P/E)21.7
Beta (1Y)0.51
Revenue Growth-7.00%
EPS Growth-12.28%
CountryUS
Employees146
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.28
Shares Outstanding3,183,818
10 Day Avg. Volume30,406
30 Day Avg. Volume33,813
Financial Highlights & Ratios
PEG Ratio-1.33
Price to Book (P/B)1.52
Price to Sales (P/S)4.71
P/FCF Ratio12.66
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Utah Medical Products Business Overview & Revenue Model
Company Description
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor an...
How the Company Makes Money
UTMD makes money by selling medical devices and related components to healthcare customers, generating revenue largely from product sales rather than services. A core driver is recurring demand for single-use/disposable products used in routine ho...
Utah Medical Products Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
93
Very Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.11M | 38.52M | 40.90M | 50.22M | 52.28M | 49.05M |
| Gross Profit | 19.82M | 19.88M | 24.14M | 30.04M | 32.20M | 30.92M |
| EBITDA | 14.67M | 17.06M | 19.57M | 24.75M | 27.74M | 26.34M |
| Net Income | 10.49M | 11.29M | 13.87M | 16.64M | 16.47M | 14.79M |
Balance Sheet | ||||||
| Total Assets | 124.57M | 122.54M | 122.54M | 135.46M | 123.87M | 115.64M |
| Cash, Cash Equivalents and Short-Term Investments | 87.53M | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total Debt | 195.00K | 225.00K | 338.00K | 295.00K | 341.00K | 396.00K |
| Total Liabilities | 2.54M | 3.27M | 5.11M | 7.14M | 9.62M | 8.50M |
| Stockholders Equity | 122.03M | 119.27M | 117.43M | 128.31M | 114.25M | 107.14M |
Cash Flow | ||||||
| Free Cash Flow | 11.45M | 14.32M | 14.60M | 21.64M | 20.33M | 20.65M |
| Operating Cash Flow | 11.85M | 14.69M | 14.83M | 22.28M | 21.15M | 21.20M |
| Investing Cash Flow | -400.00K | -371.00K | -208.00K | -639.00K | -818.00K | -552.00K |
| Financing Cash Flow | -5.79M | -12.34M | -23.84M | -4.17M | -5.48M | -10.90M |
Utah Medical Products Technical Analysis
Positive
70.96
Price Trends
70.65
Positive
68.40
Positive
64.47
Positive
Market Momentum
0.27
Positive
50.11
Neutral
38.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 70.96 is below the 20-day moving average (MA) of 71.51, above the 50-day MA of 70.65, and above the 200-day MA of 64.47, indicating a neutral trend. The MACD of 0.27 indicates Positive momentum. The RSI at 50.11 is Neutral, neither overbought nor oversold. The STOCH value of 38.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.
Utah Medical Products Risk Analysis
Utah Medical Products disclosed 10 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Utah Medical Products Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $226.37M | 21.68 | 8.74% | 1.74% | -7.00% | -12.28% | |
69 Neutral | $243.79M | 29.12 | 14.81% | ― | 2.47% | 75.23% | |
60 Neutral | $150.06M | -82.91 | -10.63% | ― | 22.41% | 60.02% | |
59 Neutral | $319.10M | -9.34 | -473.55% | 0.00% | 12.93% | -219.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
UTMD
Utah Medical Products
71.10
8.99
14.47%
INFU
InfuSystem Holdings
12.24
1.98
19.30%
KRMD
REPRO-MED Systems
3.25
-0.83
-20.34%
SMTI
Sanara MedTech
34.73
-1.02
-2.85%
Utah Medical Products Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Utah Medical Products Expands Via Orion Medical Acquisition
Positive
Aug 31, 2026
On August 31, 2026, Femcare Ltd., a wholly owned subsidiary of Utah Medical Products, Inc., completed the acquisition of all common shares of UK-based Orion Medical Supplies Ltd, a niche assembler and distributor of harm reduction medical device k...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.